Physician profile
Daniel A Pummill
NPI 1851341218
$3,809.20
in general payments reported to CMS, 2019-2025
28 companies · $72.45 in 2025
The $72.45 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $565 · 2020: $442 · 2021: $1,033 · 2022: $762 · 2023: $657 · 2024: $278 · 2025: $72.45.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,008.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,007.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $809.09 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $708.56 | 2019-2024 | Farxiga, Airsupra |
| Amgen INC. | $488.65 | 2019-2024 | Repatha, Otezla |
| Merck Sharp & Dohme LLC | $321.01 | 2019-2023 | Verquvo, Steglatro |
| Bayer Healthcare Pharmaceuticals INC. | $265.39 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $219.03 | 2019-2022 | |
| Lilly USA, LLC | $187.32 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.61 | 2019-2023 | Jardiance |
| Abbvie INC. | $94.64 | 2021-2025 | |
| Pfizer INC. | $75.65 | 2020-2023 | |
| Novartis Pharmaceuticals Corporation | $57.05 | 2021-2023 | |
| Organon LLC | $53.65 | 2021-2023 | Nexplanon |
| Allergan, INC. | $43.65 | 2019-2020 | |
| Esperion Therapeutics, INC. | $42.12 | 2021-2022 | |
| Exact Sciences Corporation | $39.52 | 2023-2024 | Cologuard Collection Kit |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $38.56 | 2019-2021 | |
| Alk-Abello, INC | $34.69 | 2024 | Grastek, Odactra, Ragwitek |
| Dexcom, INC. | $33.71 | 2021 | |
| Genentech USA, INC. | $28.63 | 2020-2021 | |
| Sanofi Pasteur INC. | $28.04 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $20.29 | 2024 | Rexulti |
| Strongbridge US INC. | $17.77 | 2019 | |
| Ironshore Pharmaceuticals INC. | $15.84 | 2019 | |
| Phathom Pharmaceuticals, INC. | $15.72 | 2024 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.18 | 2023 | Xifaxan, Trulance |
| Sumitomo Pharma America, INC. | $14.47 | 2025 | Gemtesa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.36 | 2023 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $13.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Pummill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.